To provide monoclonal antibodies capable of inhibiting the binding of RGM A to its receptor and/or coreceptor, and to provide the antibodies useful for detecting RGM A and for inhibiting RGM A activity in a human suffering from a disease including multiple sclerosis, mammal brain trauma, spinal cord injury, stroke, neurodegenerative disease and schizophrenia.SOLUTION: Provided is a binding protein that dissociates from human RGM A with a KD of 1x10-7M or less and with a koff rate constant of 1x10-2 s-1 or less (both determined by surface plasmon resonance).SELECTED DRAWING: None
MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN AND USES THEREOF